deltatrials
Completed PHASE2/PHASE3 NCT00041925

Prevention of Autogenous Vein Graft Failure in Peripheral Artery Bypass Procedures

A Phase III, Multi-Center Randomized, Double-Blind, Placebo-Controlled Trial of the Ex Vivo Treatment With CGT003 of Peripheral Vein Grafts in Patients Undergoing Peripheral Arterial Bypass Graft Procedures

Sponsor: Anesiva, Inc.

Conditions Arterial Occlusive Diseases Graft Occlusion, Vascular Hyperplasia Ischemia Peripheral Vascular Diseases
Interventions CGT003 (E2F Duplex Decoy)
Updated 6 times since 2017 Last updated: Jul 14, 2005 Started: Nov 30, 2001 Completion: Nov 30, 2004

This PHASE2/PHASE3 trial investigates Arterial Occlusive Diseases and Graft Occlusion, Vascular and is currently completed. Anesiva, Inc. leads this study, which shows 6 recorded versions since 2001 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3 → PHASE2/PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2_PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE2_PHASE3

    First recorded

Nov 2001

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Anesiva, Inc.
Data source: Anesiva, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Atlanta, United States, Baltimore, United States, Baton Rouge, United States, Birmingham, United States, Boston, United States, Brooklyn, United States, Calgary, Canada, Charleston, United States, Chesapeake, United States and 59 more location s